



# INNOVATION FOR GOOD HEALTH

持續創新 樂享健康

ESG u ESG u v — 2 ESG<sup>3-</sup> u  
u ESG w w v

a a v a v « 2  
a v «<sup>3-</sup> u a v  
« 2 3 w ESG u  
ESG — MSCI ESG w

2021 → CSR<sup>3-</sup> u  
w

2021 w

u v v w v v  
u v w v

u 2022 3 22 w

u u w  
w v

{ ir@fosunpharma.com  
{ 1289 A

1.

ESG u ESG u ESG u u v u

1.1

1.1.1

« a « u<sup>a</sup> « u<sup>a</sup>  
« u u u u u u u u u u  
W u u v v v v v v v v v v  
z u v u u u u u u u u u u  
ESG u ESG u u u u u u u u u u  
u u u u u u u u u u u u u u  
11 u 4 u u u u u u u u u u  
u u u u u u u u u u u u u u

### 1.1.2 ESG

ESG

v → ESG u w

u ESG w ESG u ESG u a

v «u v v v

w ESG u ESG u ESG w

u ESG u w ESG

ESG ESG u ESG v v ESG u

ESG w


u ESG ESG

u ESG w 2021 u ESG

ESG ESG u ESG u ESG w

2021 u u ESG w

V



**ESG**

ESG  
wESG  
ESG u  
u ESG v ESG u w  
u v ESG u

## 1.2

### 1.2.1

«U  
«V<sup>a</sup>

W

u

W

Z<sup>a</sup>

«

«W

u

u

u

a

u

a


u

W




•	W
•	W
•	u W
•	W
•	v u W v

1.2.2 ESG

ESG u ESG ESG u  
v «u ESG ESG v<sup>a</sup> GRI «  
ESG w ESG ESG u v  
u ESG u w





1.3





u a «V<sup>a</sup> v « u u  
u v w u v w  
v v v v w  
u u  
u u u w  
u u w



V

w            u            u            u            30 u            u            u

2.

<sup>2</sup> u v v v <sup>3</sup> u  
u w GxP<sup>1</sup> u  
u  
w

2.1

2.1.1

<sup>2</sup> v v <sup>3</sup> u  
u w u  
u u u  
u w  
2021 u u  
w 49.75 u 2021  
12 31 u v v v 240 w  
u a  
(SOP)«u u  
—GCP ~u z  
w  
<sup>2</sup> <sup>3</sup> w a  
«u u  
u w u 186 u  
35 v PCT 26 z 62 w

<sup>1</sup> GxP <sup>2</sup> Good x Practice<sup>3</sup>u u GMPv GAP w




2022 1 u  
—WHO-PQ u u WHO-PQ 2 30 — 26  
4 u u u  
u u u u u  
u u u v v CT w u —  
— u w  
mRNA u BioNtech u u 2022 2 u  
2 3w u<sup>2</sup> 3 u  
2,000 w  
u v (FDA)  
(TGA) u w  
u w u  
u w2022 1 u MPP  
Molnupiravir u 105 u 95 u  
Molnupiravirz 2022 3 u MPP (Paxlovid)u  
w  
u u u  
u w 2021 12 31  
u 1 — CLDT z  
9 w

2022 1 u  
 1 2 (IS)u v u u IS  
 w w u u IS/TSC u  
 v IS/TSC u IS  
 w

## 2.2

<sup>2</sup> u u u u <sup>3</sup> u u u u u  
 -2021 -2025 ~ u <sup>2</sup> 3√2 3√2 3  
 w



u u

u


u v v v  
 w 2010 GMP (Good Manufacturing Practice of Medical Productsu  
 WHO ICHQ9  
 u 2 —GMP — 3 u  
 w u  
 u w  
 w 2021 12 31 u  
 a «W  
 GMP2010 u GMP 38 v 40  
 87 u GMP 100%w u FDAv EMA—European Medicines  
 Agencyu cGMP M q5 ¼T Jj ]@=áØá U6# Z—06A 6A #j 4

w w u u u u  
w u z u u  
w u u w u  
70 v 20 w

### 2.3

#### 2.3.1

a «V<sup>a</sup> «V<sup>a</sup>  
« u u  
u w  
ArisGu u NMPAv FDA EMA u PV  
w ArisG u  
w





V

u  
w

2 3 u u  
w u u

u u u u  
w u w

u u u w  
u u u 100%

u u 100%w2021 u



3.

3.1

2021 10 31 u (COP26) w  
u a 2021 { «u u  
u w u  
{<sup>2</sup> a « u  
u w u  
u 2030 u 2060 w<sup>3</sup>  
v u  
u 2021 u (TCFD)u w

3.1.1

ESG 2021 u  
v u w ESG u  
ESG u w u ESG u  
u ESG u v  
w

3.1.2

ESG 2021 u (IPCC)  
w u (RCP)2.6 RCP8.5w u  
v u RCP2.6 v u z RCP8.5 u  
w u  
w u



u — — v  
v ~w u  
u u  
u w  
u 2 33 u w  
u u u  
u w  
u z u u  
w  
u z u  
w

3.1.3


u w  
w  
u u w u  
u v u u  
w u u  
w u w u  
u u w u

V

u v u  
u w a  
«u u  
w u w  
2021 12 31 u 5 u w

3.1.4

v v u u  
w u 137.8 u u 746.5  
v 33.9 v 5,546 w



u u v v w  
u u u

		u 2021	157.9 w	u	u	v	u	v
2021	15	u	2,659	w	u	u	u	u
	u	0.23	u	2020	15.5%w			
	u	2021	24,146	<sup>4</sup> w				
	u	2.06 GJ	u	2020	18.4%w			
		<sup>5</sup>						
		GJ	GJ	GJ	GJ			
2019		4,344,819	3,231,731	7,576,550			2.65	
2020		2,604,950	5,050,819	7,655,768			2.52	
2021		3,463,822	4,584,921	8,048,743			2.06	

<sup>4</sup>

a

— ~«W

<sup>5</sup> 2021

a


«(GB/T 2589-2020)u

a

«(GB/T 2589-2008)


w

2017–2021



2019	758,143	381,580	376,563	0.35
2020	827,858	225,622	602,236	0.27
2021	900,112	308,755	591,357	0.23

2017–2021



6 u 2019 v w u 2020 2021

7 v v v v w

8 v w

### 3.2

«<sup>a</sup> u<sup>a</sup> «V<sup>a</sup> (EHS) «u<sup>a</sup> EHS  
w EHS w u EHS u v v v EHS  
EHS EHS w u 2021<sup>a</sup> EHS EHS «u  
EHS u EHS u EHS w

#### 3.2.1

v v u EHS  
u v v u v  
EHS w u EHS u EHS  
w  
ISO14001 EHS w



EHS			
•	v	v	v
	v	v	

•	v	v
ISO14001	ISO45001	

**EHS**

u		v	z	
u			u	u
	z 11	u		u
		v		w
	u	u	u	3,341.32
u	v	v	v	z
	11,943.18	u		
w				

3.2.2

	u	v	u	v	u	u	w
2016	2020	u	EHS	z	u		
u			w2021	u		v	
	EHS	v			u	u	
(2021–2025)	w	u	EHS	u	EHS	u	
	u		w				

2021 2025

•		{ 2025	2020	20%	
•		{ 2025	2020	20%	
•		{ 2025	2020	20%	
•	2025	VOCs	100%		
•		{ 2025	2020	15%	
•		(COD)	{ 2025	2020	15%
•		{ 2025	2020	15%	
•		<sup>9</sup>	{ 2025	2019	10%
•		{ 2025	2020	15%	
•		{ 2025	2020	10%	
•		{ 2025	2020	15%	
•		{	3		

3.2.2

a

«V<sup>a</sup>

«V<sup>a</sup>

«

u

w


u

v

v

w

	NOx	SO <sub>2</sub>	(VOCs)	NHMC	NO <sub>x</sub>	<sup>10</sup> SO <sub>2</sub>	(NOx)	(SO <sub>2</sub> )
2019	258	134	36	—	—	—	—	—
2020	158	105	37	24.2	—	—	—	—
2021	182	101	25	42.9	46.61	25.91	—	6.45



<sup>10</sup> 2020

NOx, SO<sub>2</sub>

w

VOCs										
2021	u		v	v	v					
VOCs		u			600	u				v
	v	u				u		u	VOCs	
	w									
				1,600					u	
	v	VOCs			u	VOCs			v	u
					u			u	v	
		u		2				<sup>3</sup> u	760	
w										





2020 u u u v u 2 v 3  
 10.6%w u w u

---

2019	7,091,033	2.48	778	0.27	130	0.046
2020	6,505,479	2.15	655	0.22	88.5	0.03
2021	7,497,581	1.92	704	0.18	146	0.038


2019–2021






---

2019	73,584	25.74	63,629.20	22.26	4,320.80	1.51
2020	49,286	16.26	37,060.20	12.23	5,914.50	1.95
2021	66,328	17.01	60,374.70	15.48	5,953.70	1.53








3.2.3

u	v	a	«W	u	103.1
303,088	u	v	v	2020	13%w
			2.9%u		

2019	9,527,927	3.33
2020	9,381,818	3.10
2021	10,521,811	2.70







4.


$w$     $2$     $v$     $v$     $3$     $u$     $u$   
 $w$

4.1

$a$     $—$     $\sim \ll V^a$     $—$     $\sim \ll$     $u$     $u$   
 $v$     $v$     $u$     $w$     $u$   
 $v$     $v$     $v$     $w$     $w$



4.1.1

$u$     $u$     $w$     $u$     $u$     $w$   
 $u$     $w$     $u$     $w$     $u$   
 $u$



V

u  
w u  
w u  
v v u  
v v v  
u u  
w u v  
u u  
w u  
u



u u u w u  
u w


2021 12 31 u

{

68	563	88	9
50	186	71	3
155	63	14	4
23	16	118	12
13	47	103	9
110	269	2	315
32	47	5	
26	69	2	
335	71	19	

4.1.2

u u u u u  
 —Av Bv Cv D~u GMP w 4  
 w



V

v v v v u v v v  
v w v u u u u  
w w2021 u 38 w

11

---

140	670	400	62	75	25	149	137
140	780	578	62	75	25	177	137
100.0%	86.1%	69.2%	100.0%	100.0%	100.0%	84.2%	100.0%

u u u u v v v v  
u u u u w 2 3  
u w

11 u v z w





4.2.2

2 3 u  
W u a u 2 v 3  
u u «U  
u W



- v u w
- u v w



- w
- w
- u v v w



- u w
  - v v w
  - v v —EHS&Q) u
- u w



- v w
- w u
- w



- u w

u u  
w u u  
u w u u 126 w

4.2.3

u 2 3 u w u EHS a w  
« a u «u 2021 12 31 u 7,193 w w





w u u w  
2021 12 31 u v 411 w w





2021 12 31 u

36,279 u 2020

12.47%w



按僱傭類型劃分員工總數  
(人, %)





u v OA v u u v w u  
u u u w u u  
u u w u w u  
u u w u u  
u u v v v v  
u w u v w u u  
w

## 5.2

2 3W u w w  
u u w u u u u { w  
u u v u u

### 5.2.1

# V

YAO { u v v ITv v v v  
 EHS<sup>-</sup> u — v v ~u 3 w

{ u u u w


Super { u 2 YAO 3 u  
 u w u

{ u v v v v u  
 w u v v

{ v v v u u 2 3u u  
 w

## 5.2.2

2 u 3 u  
 u u 2 3v2 w 3v2 3 2 u  
 3W



•  
v u v  
u 3  
u  
w2021 u  
2  
3 u  
w

• u u  
v u  
u u  
w  
u  
u  
z  
1-2  
w

• v v u  
u w

• 2  
3u  
v  
v v  
w2021 u  
FoTED  
u 3u  
2  
u v  
u u v  
v w



V

u    2    3    u<sup>w</sup>    u    v    —

u {

14

2021

837

19

% 58%

% 53%

% 47%

19

20

% 1.3%

% 98.7%

14

20

5.2.3

<sup>2</sup> u <sup>3</sup>u v v v



w u u u u u u u w

360 u «V<sup>a</sup> u «V<sup>a</sup> «V<sup>a</sup> u<sup>a</sup> «<sup>a</sup> Pre-

IPO u u u u w u u u

21.01%w

### 按性別劃分員工流失率



5.3

5.3.1

2 v v 3 u u  
 v z v v u  
 u u w u  
 { v u 2021-2025 0.3 u 2025  
 2020 10%w u SOP u u  
 u u u w — u  
 w2021 u 282 u 0.17u  
 0.355u w

5.3.2

u u  
 w u v  
 v v u w  
 2 3 u u  
 u u w

2016-2020	u								
39% 33%u					u	2021	EHS		
(BBS)	u						w		
v v v v v v									
u								u	
u						2 3u		2	u
3		u		v v	u			2	3 w
			u		264		w		

重物吊裝  
吊裝重物砸落傷人的行為

電氣安全  
可能引起觸電、  
電氣閃弧的行為

機械防護  
接觸機械並可能  
有傷害的行為

限制空間  
未執行限制空間進入要求，  
可能造成進入人員傷亡的行為

動火作業  
吸烟等有火情隱患的行為

工藝防爆安全  
可能引起化工燃爆的行為

登高作業  
舉爬中導致人員墜落等行為

貼簽機清潔操作BBS

0:00:03 0:02:25

u v v u u v u  
v v v v u u  
u w v



**121**

2021 9 u v CSCO & v u

26 u 45 u 50 u 25,000

**使命**  
以家庭客戶為中心  
提供全方位全周期健康服務

**星爱121**  
FOSUN PHARMA  
HEALTH CARE INITIATIVE

**願景**  
讓每個家庭樂享健康





